PIK3CA H1047R substitution was shown to be associated with a low proportion of complete responses to anthracycline and taxane therapy in triple-negative breast cancer, and with resistance to anti-HER2 therapy in HER2-positive tumors [24,25]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.